Venrock Healthcare Capital Partners
Palo Alto, California, United StatesFounded 2008
Venrock Healthcare Capital Partners (VHCP) is a healthcare-focused, late-stage venture capital fund family that invests primarily in publicly-held and late-stage private companies within the healthcare and life sciences industries, with a strong emphasis on small-cap public biotech companies. It was founded in 2008 by Anders Hove as Venrock's public/crossover healthcare fund.
60% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (40% of deals). Average disclosed round size is $148.6M (across 55 rounds with reported amounts).
Portfolio
53
Fund Size
$500M
Top Stage
Series B
Last 12 Mo
6
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
63 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 CellCentric | Series D | $220M | May 2026 |
 Mirador | Series B | $250M | Jan 2026 |
 Mirador Tx | Series B | $250M | Jan 2026 |
| AAngitia Bio | Series D | $130M | Jan 2026 |
 Artiva Biotherapeutics | Series B | $120M | Jan 2026 |
| AAvere Therapeutics | Unknown | $320M | Jan 2026 |
 Metsera | Series B | $215M | Jan 2026 |
 Tubulis | Series C | — | Oct 2025 |
| TTubulis GmbH | Series C | — | Oct 2025 |
| OOruka Therapeutics Inc | Unknown | $180M | Sep 2025 |
 Crescent Biopharma | Growth | $200M | Jun 2025 |
 Surrozen | Series D | $175M | Mar 2025 |
 Timberlyne Therapeutics | Series A | $180M | Jan 2025 |
 Damora Therapeutics | Unknown | $284.9M | Jan 2025 |
| MMirador Therapeutics | Unknown | $250M | Jan 2025 |
| Mirador Tx | Series B | $250M | Jan 2025 |
 Adcendo ApS | Series B | $135M | Nov 2024 |
| Metsera | Series B | — | Nov 2024 |
 Lycia Therapeutics | Series C | $106.6M | May 2024 |
 Averto Medical | Series A | $30.5M | May 2024 |
| Mirador Tx | Unknown | $400M | Mar 2024 |
| Metsera | Series B | $215M | Jan 2024 |
 Korsana Biosciences | Seed | $25M | Jan 2024 |
| Adcendo ApS | Series B | $135M | Jan 2024 |
 ADARx Pharmaceuticals | Series C | $200M | Aug 2023 |
Page 1 of 3
Top Co-Investors
Logos Capital28 shared
OrbiMed24 shared
Wellington Management21 shared
RA Capital Management18 shared
Fairmount Funds Management17 shared
Cormorant Asset Management13 shared
Deep Track Capital11 shared
The Invus Group, LLC11 shared
Perceptive Advisors11 shared
Vivo Capital11 shared
Viking Global Investors10 shared
Surveyor Capital10 shared
RTW Investments, LP9 shared
Commodore Capital9 shared
ARCH Venture Partners9 shared
Frazier Life Sciences8 shared
Franklin Templeton8 shared
Alexandria Venture Investments8 shared
Sofinnova Partners8 shared
Last updated: 7 October 2026